Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products

Status

Not yet recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521621-33-00

Enrollment

Registered

2026-02-09

Start date

Unknown

Completion date

Unknown

Last updated

2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic Melanoma, Advanced solid tumors, Hepatocellular Carcinoma, Melanoma

Brief summary

Evaluation of delayed adverse event(s) will be based on the occurrence of: New malignancy(ies); New incidence or exacerbation of a pre-existing neurologic disorder; New incidence or exacerbation of a pre-existing rheumatologic or other autoimmune disorder; New incidence of a hematologic disorder; New incidence of infection related to RPx, New herpetic infection and presence of RPx detected in samples collected from herpetic lesions

Interventions

DRUGVusolimogene oderparepvec

DRUGRP3

DRUGRP2

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Evaluation of delayed adverse event(s) will be based on the occurrence of: New malignancy(ies); New incidence or exacerbation of a pre-existing neurologic disorder; New incidence or exacerbation of a pre-existing rheumatologic or other autoimmune disorder; New incidence of a hematologic disorder; New incidence of infection related to RPx, New herpetic infection and presence of RPx detected in samples collected from herpetic lesions	—

Measure

Time frame

—

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 10, 2026